S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NYSE:PEN

Penumbra Stock Forecast, Price & News

$266.91
+3.67 (+1.39 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$254.62
Now: $266.91
$268.09
50-Day Range
$228.46
MA: $263.80
$291.43
52-Week Range
$121.80
Now: $266.91
$314.22
Volume293,002 shs
Average Volume571,037 shs
Market Capitalization$9.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.43
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; rehabilitation tools that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Penumbra logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-748-3200
Employees2,700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$547.41 million
Cash Flow$1.50 per share
Book Value$13.91 per share

Profitability

Net Income$48.46 million

Miscellaneous

Market Cap$9.73 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

525th out of 1,972 stocks

Surgical & Medical Instruments Industry

50th out of 169 stocks

Analyst Opinion: 1.3Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$266.91
+3.67 (+1.39 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Penumbra (NYSE:PEN) Frequently Asked Questions

Is Penumbra a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Penumbra stock.
View analyst ratings for Penumbra
or view top-rated stocks.

What stocks does MarketBeat like better than Penumbra?

Wall Street analysts have given Penumbra a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Penumbra wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Penumbra?

Penumbra saw a decline in short interest during the month of January. As of January 29th, there was short interest totaling 3,660,000 shares, a decline of 39.6% from the January 14th total of 6,060,000 shares. Based on an average daily trading volume, of 834,100 shares, the short-interest ratio is currently 4.4 days. Currently, 10.8% of the company's shares are sold short.
View Penumbra's Short Interest
.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Penumbra
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) released its earnings results on Tuesday, February, 23rd. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.50. The firm had revenue of $166.90 million for the quarter, compared to analysts' expectations of $159.69 million. Penumbra had a negative trailing twelve-month return on equity of 0.12% and a negative net margin of 1.79%. Penumbra's revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.27 EPS.
View Penumbra's earnings history
.

How has Penumbra's stock been impacted by Coronavirus?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PEN stock has increased by 50.9% and is now trading at $266.91.
View which stocks have been most impacted by COVID-19
.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2021 After-Hours earnings guidance on Tuesday, February, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $675-685 million, compared to the consensus revenue estimate of $654.52 million.

What price target have analysts set for PEN?

6 brokers have issued 12 month price objectives for Penumbra's shares. Their forecasts range from $200.00 to $325.00. On average, they anticipate Penumbra's stock price to reach $279.00 in the next twelve months. This suggests a possible upside of 4.5% from the stock's current price.
View analysts' price targets for Penumbra
or view top-rated stocks among Wall Street analysts.

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Mr. Adam Elsesser, Co-Founder, Chairman, Pres & CEO (Age 59, Pay $726.69k)
  • Ms. Maggie S. Yuen, Chief Financial Officer (Age 49, Pay $643.64k)
  • Ms. Johanna Roberts, Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $530.92k)
  • Mr. James Robert Pray, Pres of International (Age 57, Pay $504.29k)
  • Ms. Lynn Rothman, Exec. VP & Chief Bus. Officer (Age 60, Pay $605.13k)
  • Dr. Arani Bose, Co-Founder, Chief Innovator & Director (Age 59)
  • Mr. Ryan Powers, VP of Operations
  • Mr. Lambert Shiu, Chief Accounting Officer (Age 41)
  • Mr. David Barry, Chief Technology Officer
  • Mr. Corey L. Teigen M.D., Chief Scientific Officer

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra CEO Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among Penumbra's employees.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), The Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (9.80%), Price T Rowe Associates Inc. MD (3.80%), William Blair Investment Management LLC (3.68%), Baillie Gifford & Co. (3.19%) and Clearbridge Investments LLC (2.98%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju and Thomas Wilder.
View institutional ownership trends for Penumbra
.

Which major investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Morgan Stanley, Federated Hermes Inc., Victory Capital Management Inc., JPMorgan Chase & Co., PFM Health Sciences LP, Clearbridge Investments LLC, and Ardevora Asset Management LLP. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, and Thomas Wilder.
View insider buying and selling activity for Penumbra
or view top insider-selling stocks.

Which major investors are buying Penumbra stock?

PEN stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Price T Rowe Associates Inc. MD, BlackRock Inc., William Blair Investment Management LLC, Wetherby Asset Management Inc., Voloridge Investment Management LLC, Baillie Gifford & Co., and Nuveen Asset Management LLC.
View insider buying and selling activity for Penumbra
or or view top insider-buying stocks.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $266.91.

How much money does Penumbra make?

Penumbra has a market capitalization of $9.73 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis.

How many employees does Penumbra have?

Penumbra employs 2,700 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

Where are Penumbra's headquarters?

Penumbra is headquartered at One Penumbra Place, Alameda CA, 94502.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.